Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG01CI in Fragile X Syndrome
NCT02126995Phase 2Completed
- Sponsor
- Alcobra Ltd.
- Start
- Jun 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of Metadoxine in Fragile X syndrome (FXS), sponsored by Alcobra Ltd.. Started Jun 2014; status: completed.
02
Drugs
Metadoxine
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT02126995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02126995.